Literature DB >> 22379121

Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response.

Rahul Srinivasan1, Christopher I Richards, Cheng Xiao, Doreen Rhee, Rigo Pantoja, Dennis A Dougherty, Julie M Miwa, Henry A Lester.   

Abstract

We report the first observation that endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) can decrease when a central nervous system drug acts as an intracellular pharmacological chaperone for its classic receptor. Transient expression of α4β2 nicotinic receptors (nAChRs) in Neuro-2a cells induced the nuclear translocation of activating transcription factor 6 (ATF6), which is part of the UPR. Cells were exposed for 48 h to the full agonist nicotine, the partial agonist cytisine, or the competitive antagonist dihydro-β-erythroidine; we also tested mutant nAChRs that readily exit the ER. Each of these four manipulations increased Sec24D-enhanced green fluorescent protein fluorescence of condensed ER exit sites and attenuated translocation of ATF6-enhanced green fluorescent protein to the nucleus. However, we found no correlation among the manipulations regarding other tested parameters [i.e., changes in nAChR stoichiometry (α4(2)β2(3) versus α4(3)β2(2)), changes in ER and trans-Golgi structures, or the degree of nAChR up-regulation at the plasma membrane]. The four manipulations activated 0 to 0.4% of nAChRs, which shows that activation of the nAChR channel did not underlie the reduced ER stress. Nicotine also attenuated endogenously expressed ATF6 translocation and phosphorylation of eukaryotic initiation factor 2α in mouse cortical neurons transfected with α4β2 nAChRs. We conclude that, when nicotine accelerates ER export of α4β2 nAChRs, this suppresses ER stress and the UPR. Suppression of a sustained UPR may explain the apparent neuroprotective effect that causes the inverse correlation between a person's history of tobacco use and susceptibility to developing Parkinson's disease. This suggests a novel mechanism for neuroprotection by nicotine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22379121      PMCID: PMC3362896          DOI: 10.1124/mol.112.077792

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  61 in total

1.  Ultrastructural localization of phosphorylated eIF2alpha [eIF2alpha(P)] in rat dorsal hippocampus during reperfusion.

Authors:  E N Goldstein; C R Owen; B C White; J A Rafols
Journal:  Acta Neuropathol       Date:  1999-11       Impact factor: 17.088

2.  Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path.

Authors:  Raad Nashmi; Cheng Xiao; Purnima Deshpande; Sheri McKinney; Sharon R Grady; Paul Whiteaker; Qi Huang; Tristan McClure-Begley; Jon M Lindstrom; Cesar Labarca; Allan C Collins; Michael J Marks; Henry A Lester
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

Review 3.  Heterogeneity and complexity of native brain nicotinic receptors.

Authors:  Cecilia Gotti; Milena Moretti; Annalisa Gaimarri; Alessio Zanardi; Franceso Clementi; Michele Zoli
Journal:  Biochem Pharmacol       Date:  2007-06-02       Impact factor: 5.858

4.  Intracellular complexes of the beta2 subunit of the nicotinic acetylcholine receptor in brain identified by proteomics.

Authors:  Nadine Kabbani; Matthew P Woll; Robert Levenson; Jon M Lindstrom; Jean-Pierre Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-10       Impact factor: 11.205

5.  ATF6alpha induces XBP1-independent expansion of the endoplasmic reticulum.

Authors:  Hemamalini Bommiasamy; Sung Hoon Back; Paolo Fagone; Kyungho Lee; Sasha Meshinchi; Elizabeth Vink; Rungtawan Sriburi; Matthew Frank; Suzanne Jackowski; Randal J Kaufman; Joseph W Brewer
Journal:  J Cell Sci       Date:  2009-05-15       Impact factor: 5.285

6.  Dopamine selectively sensitizes dopaminergic neurons to rotenone-induced apoptosis.

Authors:  Ferogh A Ahmadi; Tom N Grammatopoulos; Andy M Poczobutt; Susan M Jones; Laurence D Snell; Mita Das; W Michael Zawada
Journal:  Neurochem Res       Date:  2007-11-10       Impact factor: 3.996

7.  Nicotine normalizes intracellular subunit stoichiometry of nicotinic receptors carrying mutations linked to autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Cagdas D Son; Fraser J Moss; Bruce N Cohen; Henry A Lester
Journal:  Mol Pharmacol       Date:  2009-02-23       Impact factor: 4.436

8.  Eukaryotic initiation factors (eIF) 2alpha and 4E expression, localization, and phosphorylation in brain tumors.

Authors:  Sonia Tejada; M Val T Lobo; Mercedes García-Villanueva; Silvia Sacristán; M Isabel Pérez-Morgado; Matilde Salinas; M Elena Martín
Journal:  J Histochem Cytochem       Date:  2009-02-02       Impact factor: 2.479

Review 9.  Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery.

Authors:  Henry A Lester; Cheng Xiao; Rahul Srinivasan; Cagdas D Son; Julie Miwa; Rigo Pantoja; Matthew R Banghart; Dennis A Dougherty; Alison M Goate; Jen C Wang
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

10.  Nicotine regulates multiple synaptic proteins by inhibiting proteasomal activity.

Authors:  Khosrow Rezvani; Yanfen Teng; David Shim; Mariella De Biasi
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

View more
  36 in total

1.  Live-cell imaging of single receptor composition using zero-mode waveguide nanostructures.

Authors:  Christopher I Richards; Khai Luong; Rahul Srinivasan; Stephen W Turner; Dennis A Dougherty; Jonas Korlach; Henry A Lester
Journal:  Nano Lett       Date:  2012-06-08       Impact factor: 11.189

Review 2.  Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects.

Authors:  Henry A Lester; Julie M Miwa; Rahul Srinivasan
Journal:  Biol Psychiatry       Date:  2012-07-06       Impact factor: 13.382

3.  Mechanisms of inhibition and potentiation of α4β2 nicotinic acetylcholine receptors by members of the Ly6 protein family.

Authors:  Meilin Wu; Clare A Puddifoot; Palmer Taylor; William J Joiner
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

Review 4.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

5.  Biosynthesis of ionotropic acetylcholine receptors requires the evolutionarily conserved ER membrane complex.

Authors:  Magali Richard; Thomas Boulin; Valérie J P Robert; Janet E Richmond; Jean-Louis Bessereau
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

6.  Nicotinic receptor subtype-selective circuit patterns in the subthalamic nucleus.

Authors:  Cheng Xiao; Julie M Miwa; Brandon J Henderson; Ying Wang; Purnima Deshpande; Sheri L McKinney; Henry A Lester
Journal:  J Neurosci       Date:  2015-03-04       Impact factor: 6.167

7.  Ly6h regulates trafficking of alpha7 nicotinic acetylcholine receptors and nicotine-induced potentiation of glutamatergic signaling.

Authors:  Clare A Puddifoot; Meilin Wu; Rou-Jia Sung; William J Joiner
Journal:  J Neurosci       Date:  2015-02-25       Impact factor: 6.167

8.  Chronic Menthol Does Not Change Stoichiometry or Functional Plasma Membrane Levels of Mouse α3β4-Containing Nicotinic Acetylcholine Receptors.

Authors:  Selvan Bavan; Charlene H Kim; Brandon J Henderson; Henry A Lester
Journal:  Mol Pharmacol       Date:  2019-01-22       Impact factor: 4.436

Review 9.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

10.  Proteomic Investigation of Murine Neuronal α7-Nicotinic Acetylcholine Receptor Interacting Proteins.

Authors:  Matthew J Mulcahy; Joao A Paulo; Edward Hawrot
Journal:  J Proteome Res       Date:  2018-10-04       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.